moxifloxacin

Wound Infections: a Role of Microbiological Monitoring for the Hospital Antimicrobial Policy

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(4):368-375

During the last 7 years the leading pathogens in the etiology of skin and soft tissue infections in the hospital were Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli and Pseudomonas аeruginosа. Statistical prognosis does not suggest …

Pharmacokinetic Study of Moxifloxacin in Chronic Pancreatitis Complicated with Pancreatic Cysts

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(3):255-260

Infectious complications of pancreatic cysts (PC) is one of the problem of modern medicine due to insufficient data on pharmacokinetic of majority of antimicrobials resulting to the lack of standards for antimicrobial therapy and prophylaxis of this …

Moxifloxacin: the Present and the Future in the Sequential Therapy

Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):19-31

Moxifloxacin is a new broad spectrum 8-meth-oxiquinolon with high activity against both Gram(+) and Gram(–) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other …

Moxifloxacin – the New Fluoroquinolone with Broad Spectrum of Activity

Clinical Microbiology and Antimicrobial Chemotherapy. 2001; 3(3):243-259

Moxifloxacin – new broad spectrum 8-methoxyquinolon with high activity against Gram(+) and Gram(-) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other classes …